In combination, the findings by Chauvette et al. (2012) and Grosmark et al. (2012) do not question the concept of global synaptic downscaling during sleep but instead suggest that processes during REM sleep should be taken into consideration. Beyond this, Grosmark et al.'s findings offer an interesting link between global processes of downscaling and the consolidation of specific memories in local networks, because they analyze firing occurring in the presence of hippocampal ripples, which regularly accompany the neuronal replay of newly encoded memory representations from the prior waking period (O'Neill et al., 2010) . Ripple-associated replay during SWS has been considered the key mechanism launching the consolidation of newly acquired episodic memories (Diekelmann and Born, 2010) . Grosmark et al. report that during ripples, cells fire more synchronously, and this firing paradoxically increases across NonREM-REMNonREM sleep triplets. Moreover, the increased synchronous within-ripple firing occurred especially in those neuron assemblies that fired with high theta and gamma activity during interleaving REM epochs. The data tempt us to speculate that global processes of downscaling occur in concert with local processes of upscaling and shaping of memory representations across the sleep cycle in an interplay between ripple-associated and theta-associated replay activity. It has been proposed that one function of theta-associated replay might be to select memories for consolidation as, depending on the phase of the theta cycle, replay during theta potentiates or depotentiates the activated synaptic assemblies (Poe et al., 2000) . Whatever the case, the findings by Grosmark et al. (2012) suggest that both global synaptic downscaling and local upscaling of specific memory representations originate from sequenced processes across the NonREM-REM sleep cycle. Future research might reveal that these global and local processes are inextricably tied to each other in jointly establishing sleep and memory. defined, and other leads to uncover these early events are very scarce. However, most patients suffering from PD or AD are apparently sporadic, which makes it hard to develop generalized hypotheses on the causality of the disease, and it remains uncertain to what extent we can generalize the conclusions from studies on rare familial mutations. The fact that some of these familial genes are also risk factors for sporadic cases supports the idea that familial and sporadic forms share a common etiology and strengthen their validity as starting points for mechanistic studies. On the other hand, animal models that model these human mutations generally do not recapitulate the clinical features observed in patients. A new study in this issue of Neuron indicates that we may need to take smaller steps and first go through the trouble of understanding the biological functions of genes associated with neurodegeneration before focusing on the clinical and pathological aspects. In doing so, neurodegeneration in animal models turns out to be only one step away in the case of the PD gene LRRK2. And as a result, the focus of neurodegeneration research is shifting back to the synapse.
The identification of single genetic factors that appear to be causal for neurodegeneration has been rather successful, especially for PD. Family studies have provided a rich collection of possible starting points for mechanistic studies (see Cookson and Bandmann, 2010) . Mutations in the presynaptic protein a-synuclein were the first to be identified in familial PD. Because a-synuclein is also the major component of the insoluble protein aggregates or Lewy bodies in the brain of patients, the initial focus of many PD studies has been on synapses. The subsequent identification of mutations in Parkin, an ubiquitin E3 ligase, together with the reported mutations of the deubiquitinating enzyme UCH-L1 in a single PD family, has shifted much of the research of the past decade on the pathological consequences of misfolded proteins on the ubiquitin proteasome system and how this contributes to pathogenesis, especially after a-synuclein was found also to inhibit apoptosis activation through oligomerization with cytochrome C and to exert a protective function by modulating S phase checkpoint responses. In addition, mutations in PD genes PINK, DJ-1, and ATP13A2 have implicated mitochondrial dysfunction in the pathogenesis of PD (see Cookson and Bandmann, 2010) . Together, all these findings have shifted the focus of many PD studies to cell and mitochondrial stress as the central aspect of pathogenesis.
In 2004, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene were found to cause late-onset PD that is clinically indistinguishable from idiopathic disease (Paisá n- Ruíz et al., 2004; Zimprich et al., 2004) . LRRK2 encodes a multidomain protein with kinase and GTPase activities enriched in brain. The by far most common human mutation G2019S, located in the kinase domain, has a frequency of 1% in sporadic patients and 4% in patients with familial PD. However, pathogenic mutations in the GTPase domain have also been identified. Cell biological studies, mostly using overexpression of LRRK2, show that the most common disease-associated mutations influence kinase activity in vitro, accompanied by increases in apparent neurotoxicity.
A new study addressing the physiological roles of LRRK2 by the laboratories of De Strooper and Verstreken (Matta et al., 2012) has now identified EndophilinA as a substrate of the Drosophila ortholog. EndophilinA is a presynaptic membranebinding protein with curvature-generating and -sensing properties that participates in clathrin-dependent endocytosis of synaptic vesicle membranes. The protein is highly conserved in evolution, down to yeast (Rvs167). Mammals express three isoforms. EndophilinA forms dimers via the N-terminal N-BAR domain, which insert into lipids and recruit other important endocytic proteins such as the phosphoinositide phosphatase synaptojanin required for uncoating recycling vesicles in the nerve terminal (Gallop et al., 2006; Milosevic et al., 2011) .
The study first describes the synaptic phenotype of LRRK2-deficient fly neuromuscular junction, uses an elegant in vivo genetic approach to identify EndophilinA as a modifying gene, then demonstrates that EndophilinA is an LRRK2 substrate in vitro and in vivo, identifies the residue in the protein that is phosphorylated (in its Bin/Amphiphysin/Rvs [BAR] domain), and finally characterizes the functional consequences of abnormal LRRK-dependent EndophilinA phosphorylation at the molecular and cellular level by expressing phosphomutants of EndophilinA and the most common patient mutant (G2019S) in LRRK2. These functional consequences are quite pronounced: at the molecular level, loss of membrane binding and the ability of EndophilinA to deform (tubulate) membranes are consistent with the predicted effect of altering the structure of the BAR domain. At the cellular level, FM dye uptake, a measure for endocytosis, and synaptic transmission during intense stimulation were reduced.
Despite almost 1,000 papers on LRRK in PubMed, information about the identity of its substrates is very scarce, except for the relatively well-established autophosphorylation. The in vitro and in vivo evidence for EndophilinA obtained by several independent approaches in the study by Matta et al. (2012) probably make EndophilinA the most convincing LRRK2 substrate to date. Together, these data provide a plausible and novel hypothesis about why LRRK2 mutations found in PD patients are pathogenic. Chronic deregulation of synaptic vesicle membrane retrieval might underlie a slowly progressing and age-dependent loss of synapse function and eventually the clinical manifestations observed in PD. Furthermore, the identification of EndophilinA as an LRRK2 substrate also provides intriguing links to other recent findings. First, the ubiquitin-like domain of another PD gene, Parkin, was recently shown to bind and ubiquitinate EndophilinA in vitro, and phosphatase inhibitors change EndophilinA subcellular distribution in isolated mouse nerve terminals (Trempe et al., 2009 ). Hence, a second PD gene probably regulates EndophilinA levels and function in synapses, and chronic disregulation of EndophilinA function may contribute to the pathology observed both in families carrying mutations in Parkin or in LRRK2. Second, in mice, loss of EndophilinA function leads to widespread neurodegeneration (Milosevic et al., 2011) .
Neurodegeneration in null mutant mice for presynaptic genes is quite rare and poorly understood. The often lethal phenotypes prevent analysis beyond birth. LRRK2 null mutants and also knockin mice expressing a familial mutation, R1441C, appear to have normal brains and show no degeneration up to old age (but do have a-synuclein accumulations in the kidney; Tong et al., 2009 Tong et al., , 2010 , but double null mutants for its substrate EndophilinA1/2 show numerous vacuolar spaces containing membranes and cell debris reminiscent of spongiform neurodegeneration already soon after birth (Milosevic et al., 2011) . It is not clear how well these features resemble degeneration observed in PD patients. Of course, EndophilinA function is completely lost in the null mutant mouse and degeneration is evident soon after birth, while LRRK2 dysregulation would at most confer a very partial loss of EndophilinA function. Furthermore, degeneration in the null mutant is not restricted to the dopamine system, and progression cannot be followed because the EndophilinA mutants die within weeks, but it seems plausible that more subtle and slowly developing forms of this type of neurodegeneration eventually contribute to neuronal loss observed in PD patients.
Why EndophilinA loss-of-function mice show degeneration is an intriguing open question. It seems unlikely that this degeneration is simply the result of a defective synaptic vesicle cycle. First, synaptic transmission is reduced but certainly not blocked in EndophilinA mutant neurons (Milosevic et al., 2011) and, second, other mutants with stronger defects show no sign of degeneration until birth, such as the syb2/VAMP2 or synaptotagmin1 or À2 null mutants. Such mutants typically show severe defects in synaptic transmission and paralysis, but no brain degeneration, and neurons from the prenatal brains of these mutants can be maintained in culture for weeks without signs of neuronal loss. A mutant that is completely devoid of synaptic transmission, and also of spontaneous events, still shows no sign of degeneration at birth and neurons can be maintained in culture (Varoqueaux et al., 2002) . Hence, a defective synaptic vesicle cycle seems an unlikely explanation for the observed neurodegeneration in EndophilinA loss-of-function mice. Only a limited number of loss-of-function models for presynaptic proteins show neurodegeneration like EndophilinA mice. Among the few examples are null mutants for Munc18-1, cysteine string protein (CSP), and SNAP25 (the latter only in cultured neurons). It is difficult to assess whether these models have something in common and what that might be. At least the latter two seem connected because CSP is a SNAP25 chaperone and degeneration in the CSP null mutant mice is due to impaired SNAP25 function (Chandra et al., 2005) . Interestingly, CSP lethality and neurodegeneration are rescued by overexpression of the familial PD gene a-synuclein (Sharma et al., 2012) . Another question that remains open is why dopaminergic neurons are preferentially affected in PD. The distribution of neither LRRK2 nor EndophilinA provides clues to this issue.
Interestingly, the study of Matta et al. (2012) shows that both an LRRK2 patient mutation, generally accepted as a gain of function, as well as the loss of the kinase by genetic deletion produce a similar defect on synaptic function. In line with this, transfection studies in human heterologous cells show that both kinaseactivating mutations and kinase-dead mutations have similar (toxic) effects (see Cookson and Bandmann, 2010) . Apparently, the balance between phosphorylated and nonphosphorylated substrates is delicate and needs to be maintained within a specific window. In addition, an active phosphorylation-dephosphorylation cycle seems to be required, as both the phosphomimicking and nonphosphorylatable versions of EndophilinA produce similar synaptic defects.
It remains to be determined how different human mutations in LRRK2 should be interpreted in the light of the current findings. Sporadic PD is a lateonset disease and familial cases carrying LRRK2 mutations are typically also late onset. Despite the presence of this genetic defect from birth onward, clinical symptoms take decades to become clinically evident. In addition, the identified human LRRK2 mutations show a clearly reduced penetrance. For example, the risk of PD for a person with an LRRK2 G2019S mutation that was investigated by Matta et al. (2012) increases with age. At the age of 59 it is 28%, at age 69 it is 51%, and at the age of 79 years it is 74% (Healy et al., 2008) . One can therefore expect that the biological functions affected by the mutation are not essential and are likely to have only a very mild effect on important biological processes like synaptic transmission. The relatively mild effects even of complete deletion of LRRK expression in the study by Matta et al. (2012) are in line with this.
Still, it is quite remarkable that despite the intense interest for LRRK2 and the availability of mutant mice and cell models for this kinase, the endocytosis defects have not been observed before, except for some scattered observations (Shin et al., 2008; Piccoli et al., 2011) . In addition to the fact that the overall effects on synaptic transmission are mild, a second reason might be that the primary goal of many researchers creating and studying animal models for neurodegeneration has been to recapitulate the clinical and pathological findings of the human disease. Unfortunately, not many such models exist despite a wide range of models generated in different species. One could therefore wonder whether it is even realistic to have these expectations. Maybe the differences between humans and animal species in, for example, brain organization and life span are simply too large? However, animal models do exist that each mimic different aspects of the disease such as the pathological aggregation of misfolded proteins like a-synuclein. Often this requires the construction of complex models like double or triple transgenics to show clear phenotypes, while the actual biological mechanisms resulting from the pathogenic mutations have received far less attention. Hence, considering the expected effect size of the pathogenic mutations, the question arises whether the field has studied in enough molecular detail the existing models and especially those models that mimic the human mutations or even the human genomic locus without overexpression or other additional manipulations.
Hippocampal dentate granule cell abnormalities are thought to play a causative role in temporal lobe epilepsy, but their precise contribution has not been dissociated from coexisting pathological changes. In this issue of Neuron, Pun et al. (2012) show, for the first time, that inducing proexcitatory changes in a subset of DGCs in isolation is sufficient to cause epilepsy in a rodent.
The epilepsies are a diverse group of disorders in which seizures are the defining manifestation. Seizure initiation and spread in temporal lobe epilepsy (TLE), one of the most common and intractable epilepsies in adolescents and adults, is thought to involve medial temporal structures, such as the hippocampus, parahippocampal regions, and amygdala. These regions often display distinct histopathology, the hallmark of which is Ammon's horn sclerosis (AHS). AHS is characterized by pronounced pyramidal and hilar neuronal cell death, astrogliosis, and proexcitatory reorganization of dentate granule cells (DGCs). The dentate gyrus typically acts as a ''gate'' for excitatory input to the hippocampus, and accumulating evidence suggests that DGC reorganization in experimental TLE breaks down this gating function (Pathak et al., 2007) . As a result, DGC structural remodeling is hypothesized to be pro-epileptogenic.
Under normal conditions, DGCs receive strong feedforward and feedback inhibition and do not synapse onto one another. Their somas reside in the granule cell layer and they extend apical dendrites into the molecular layer and axons into the hilus and statum lucidum of area CA3 ( Figure 1A ). DGCs synapse onto mossy cells and inhibitory interneurons in the hilus, and onto pyramidal cells in CA3. In human and experimental TLE, DGC somas may enlarge, some are found ectopically in the hilus and molecular layer, a subset display basal dendrites extending abnormally into the hilus, and DGC axon collaterals sprout into the inner molecular layer ( Figure 1B) , a process known as mossy fiber sprouting. These changes are associated with increased excitatory input and aberrant DGC interconnectivity (Parent, 2007) and are believed to promote hypersynchronous spread of excitation through the hippocampus. Recent work also implicates altered adult DGC neurogenesis in experimental TLE (Jessberger et al., 2007; Kron et al., 2010; Parent et al., 2006; Walter et al., 2007) . DGCs that develop during or after an epileptogenic insult appear to be most susceptible to aberrant integration that may cause hyperexcitability (Jessberger et al., 2007; Kron et al., 2010; Walter et al., 2007) , and suppressing adult neurogenesis variably attenuates the seizure phenotype in rodent models of TLE (Jung et al., 2004) . In contrast, normally integrated, adultgenerated DGCs may play an anti-epileptogenic role (Jakubs et al., 2006) . To date, it has been difficult to distinguish between changes that are pathological and those that are not functionally relevant or perhaps even homeostatic in TLE.
In this issue, Pun et al. (2012) induce abnormal integration of DGCs in relative isolation to determine whether this is sufficient to cause epilepsy. To accomplish this, they conditionally ablate the
